What are Monoclonal antibody; integrin antagonist drugs?

Monoclonal antibody; integrin antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting α4β1 integrin (VLA-4)). 5 are currently marketed, with 1 more in clinical development.

What are the marketed Monoclonal antibody; integrin antagonist drugs?

Marketed Monoclonal antibody; integrin antagonist drugs include Natalizumab (Tysabri), BG00002 (natalizumab), Vedolizumab SC, natalizumab (NTZ), Vedolizumab IV.

Monoclonal antibody; integrin antagonist

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

5 marketed 1 in Phase 3

This page covers all Monoclonal antibody; integrin antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting α4β1 integrin (VLA-4), α4β1 integrin, α4β7 integrin.

Targets

α4β1 integrin (VLA-4) · α4β1 integrin · α4β7 integrin · Integrins (α4β1, αLβ2, and other integrin subtypes)

Marketed (5)

Natalizumab (Tysabri) · Cornerstone Health Care, PA · Immunology; Neurology; Gastroenterology
Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing them from crossing the blood-brain barrier and entering the central nervous system.
BG00002 (natalizumab) · Biogen · Immunology / Neurology
Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing their migration across the blood-brain barrier into the central nervous system.
Vedolizumab SC · Takeda · Immunology / Gastroenterology
Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on gut-homing lymphocytes, preventing their migration to the gastrointestinal tract.
natalizumab (NTZ) · University Hospital, Clermont-Ferrand · Immunology / Neurology
Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing their migration across the blood-brain barrier into the central nervous system.
Vedolizumab IV · Takeda · Immunology / Gastroenterology
Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on gut-homing lymphocytes, preventing their migration to the gastrointestinal tract.

Phase 3 pipeline (1)

Tavilermide ophthalmic solution · Mimetogen Pharmaceuticals USA, Inc. · Ophthalmology
Tavilermide is a small-molecule integrin antagonist that inhibits cell adhesion and migration by blocking integrin-mediated interactions, reducing inflammatory cell infiltration in ocular tissues.

Patent intelligence

integrin antagonist patent landscape — aggregated cliff calendar, attackable patents, originator estates